טוען...
Initial Experience With Lung Cancer Resection Following Treatment With T Cell Checkpoint Inhibitor Therapy
T cell checkpoint inhibitors targeting the programmed death receptor-1 (PD-1) and its ligand (PDL-1) have recently been approved for the treatment of metastatic non-small cell lung cancer (NSCLC), but their safety and efficacy as neoadjuvant therapy are still undefined. Autoimmune toxicities, notabl...
שמור ב:
| הוצא לאור ב: | Ann Thorac Surg |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5572805/ https://ncbi.nlm.nih.gov/pubmed/28838509 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.athoracsur.2017.03.038 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|